Raphaël RODRIGUEZ

Raphaël Rodriguez, PhD, FRSC, is a Research Director at the CNRS and a Senior Principal Investigator at Institut Curie where he holds the Marie Curie Chair of Chemical Biology. He trained as a PhD student, then a postdoctoral scientist under the mentorships of Sir J. E. Baldwin (Oxford, 2004) and Sir S. Balasubramanian (Cambridge, 2005) from whom he acquired the knowledge of chemistry. He then trained in biology with Sir S. P. Jackson (Cambridge, 2009) with whom he co-founded Adrestia Therapeutics. At the age of 32, he established his laboratory at ICSN (Gif-sur-Yvette, 2012). He then moved to Institut Curie (Paris, 2015) to investigate the molecular bases underlying the biology of cancer. There, Rodriguez discovered the central role metals in the regulation of cell plasticity and founded Metal Therapeutics shortly after. He is a Fellow of the Royal Society of Chemistry (FRSC) and received a Knighthood of the National Order of Merit from Jean-Marie Lehn on behalf of French President Emmanuel Macron. He has received a few accolades for his scientific contribution including the Klaus Grohe Prize, Tetrahedron Young Investigator Award, Prix Lacassagne (Collège de France) and Grand Prix Charles Defforey (Institut de France).